Loading...

Rohto Pharmaceutical

OTCPK:RPHC.F
Snowflake Description

Flawless balance sheet with questionable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RPHC.F
OTCPK
¥354B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Rohto Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The last earnings update was 69 days ago. More info.


Add to Portfolio Compare Print
RPHC.F Share Price and Events
7 Day Returns
0%
OTCPK:RPHC.F
-3.4%
US Pharmaceuticals
-0.1%
US Market
1 Year Returns
-
OTCPK:RPHC.F
6.9%
US Pharmaceuticals
7.6%
US Market
RPHC.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Rohto Pharmaceutical (RPHC.F) 0% 0% 0% - - -
US Pharmaceuticals -3.4% -5.1% -1.1% 6.9% 6.3% 13.3%
US Market -0.1% 3.7% 10.2% 7.6% 38.1% 46.4%
1 Year Return vs Industry and Market
  • No trading data on RPHC.F.
  • No trading data on RPHC.F.
Price Volatility
RPHC.F
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Rohto Pharmaceutical's competitors could be found in our database.

RPHC.F Value

 Is Rohto Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Rohto Pharmaceutical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Rohto Pharmaceutical.

OTCPK:RPHC.F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:RPHC.F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.67
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.675 (1 + (1- 30.86%) (1.66%))
0.787
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%)
7.5%

Discounted Cash Flow Calculation for OTCPK:RPHC.F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Rohto Pharmaceutical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:RPHC.F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (JPY, Millions) Source Present Value
Discounted (@ 7.5%)
2019 11,250.00 Analyst x1 10,465.31
2020 11,855.00 Analyst x2 10,258.90
2021 13,360.00 Analyst x2 10,754.87
2022 14,400.00 Analyst x1 10,783.53
2023 16,800.00 Analyst x1 11,703.27
2024 18,262.16 Est @ 8.7% 11,834.50
2025 19,524.32 Est @ 6.91% 11,769.91
2026 20,628.80 Est @ 5.66% 11,568.34
2027 21,614.62 Est @ 4.78% 11,275.72
2028 22,514.69 Est @ 4.16% 10,926.03
Present value of next 10 years cash flows ¥111,340.38
OTCPK:RPHC.F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ¥22,514.69 × (1 + 2.73%) ÷ (7.5% – 2.73%)
¥485,095.34
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ¥485,095.34 ÷ (1 + 7.5%)10
¥235,409.11
OTCPK:RPHC.F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ¥111,340.38 + ¥235,409.11
¥346,749.48
Equity Value per Share
(JPY)
= Total value / Shares Outstanding
= ¥346,749.48 / 113.97
¥3042.5
OTCPK:RPHC.F Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in OTCPK:RPHC.F represents 0.00853x of TSE:4527
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.00853x
Value per Share
(Listing Adjusted, USD)
= Value per Share (JPY) x Listing Adjustment Factor
= ¥ 3,042.50 x 0.00853
$25.97
Value per share (USD) From above. $25.97
Current discount Discount to share price of $26.50
= -1 x ($26.50 - $25.97) / $25.97
-2.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Rohto Pharmaceutical is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Rohto Pharmaceutical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Rohto Pharmaceutical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:RPHC.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in JPY ¥88.27
TSE:4527 Share Price ** TSE (2019-01-24) in JPY ¥3105
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 18.77x
United States of America Market PE Ratio Median Figure of 3,080 Publicly-Listed Companies 18.03x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Rohto Pharmaceutical.

OTCPK:RPHC.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4527 Share Price ÷ EPS (both in JPY)

= 3105 ÷ 88.27

35.18x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rohto Pharmaceutical is overvalued based on earnings compared to the US Pharmaceuticals industry average.
  • Rohto Pharmaceutical is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Rohto Pharmaceutical's expected growth come at a high price?
Raw Data
OTCPK:RPHC.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 35.18x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
13.6%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 23 Publicly-Listed Pharmaceuticals Companies 1.49x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.55x

*Line of best fit is calculated by linear regression .

OTCPK:RPHC.F PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 35.18x ÷ 13.6%

2.58x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rohto Pharmaceutical is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Rohto Pharmaceutical's assets?
Raw Data
OTCPK:RPHC.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in JPY ¥1,171.41
TSE:4527 Share Price * TSE (2019-01-24) in JPY ¥3105
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 182 Publicly-Listed Pharmaceuticals Companies 3.49x
United States of America Market PB Ratio Median Figure of 5,185 Publicly-Listed Companies 1.92x
OTCPK:RPHC.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4527 Share Price ÷ Book Value per Share (both in JPY)

= 3105 ÷ 1,171.41

2.65x

* Primary Listing of Rohto Pharmaceutical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rohto Pharmaceutical is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Rohto Pharmaceutical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Rohto Pharmaceutical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RPHC.F Future Performance

 How is Rohto Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Rohto Pharmaceutical expected to grow at an attractive rate?
  • Rohto Pharmaceutical's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Rohto Pharmaceutical's earnings growth is expected to exceed the United States of America market average.
  • Rohto Pharmaceutical's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:RPHC.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:RPHC.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 13.6%
OTCPK:RPHC.F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 3.3%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:RPHC.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:RPHC.F Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-03-31 216,000 1
2023-03-31 209,500 24,300 22,200 1
2022-03-31 202,700 21,900 19,800 1
2021-03-31 194,650 19,678 14,593 4
2020-03-31 188,475 18,338 13,505 4
2019-03-31 183,190 16,178 13,030 4
OTCPK:RPHC.F Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2018-12-31 182,328 10,058
2018-09-30 180,503 21,530 10,959
2018-06-30 176,543 10,454
2018-03-31 171,742 19,154 9,289
2017-12-31 167,286 11,699
2017-09-30 161,799 15,750 11,467
2017-06-30 157,557 10,913
2017-03-31 154,599 13,428 10,011
2016-12-31 158,115 9,705
2016-09-30 160,973 9,355 8,416
2016-06-30 164,467 9,143
2016-03-31 167,016 11,324 9,098

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Rohto Pharmaceutical's earnings are expected to grow by 13.6% yearly, however this is not considered high growth (20% yearly).
  • Rohto Pharmaceutical's revenue is expected to grow by 3.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:RPHC.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Rohto Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:RPHC.F Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-03-31
2023-03-31 194.90 194.90 194.90 1.00
2022-03-31 173.80 173.80 173.80 1.00
2021-03-31 128.07 153.60 97.40 4.00
2020-03-31 118.53 135.20 95.60 4.00
2019-03-31 112.98 116.93 109.70 3.00
OTCPK:RPHC.F Past Financials Data
Date (Data in JPY Millions) EPS *
2018-12-31 88.27
2018-09-30 96.19
2018-06-30 91.77
2018-03-31 81.54
2017-12-31 102.70
2017-09-30 100.68
2017-06-30 95.83
2017-03-31 87.94
2016-12-31 85.29
2016-09-30 73.99
2016-06-30 80.41
2016-03-31 80.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Rohto Pharmaceutical is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Rohto Pharmaceutical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Rohto Pharmaceutical has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RPHC.F Past Performance

  How has Rohto Pharmaceutical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Rohto Pharmaceutical's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Rohto Pharmaceutical's year on year earnings growth rate has been positive over the past 5 years.
  • Rohto Pharmaceutical's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Rohto Pharmaceutical's 1-year earnings growth is negative, it can't be compared to the US Pharmaceuticals industry average.
Earnings and Revenue History
Rohto Pharmaceutical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Rohto Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:RPHC.F Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 182,328.00 10,058.00 80,189.00 6,553.00
2018-09-30 180,503.00 10,959.00 78,752.00 6,553.00
2018-06-30 176,543.00 10,454.00 76,177.00 6,553.00
2018-03-31 171,742.00 9,289.00 74,106.00 6,553.00
2017-12-31 167,286.00 11,699.00 72,440.00 6,123.00
2017-09-30 161,799.00 11,467.00 69,929.00 6,123.00
2017-06-30 157,557.00 10,913.00 68,783.00 6,123.00
2017-03-31 154,599.00 10,011.00 68,414.00 6,123.00
2016-12-31 158,115.00 9,705.00 69,538.00 5,811.00
2016-09-30 160,973.00 8,416.00 73,002.00 5,811.00
2016-06-30 164,467.00 9,143.00 74,140.00 5,811.00
2016-03-31 167,016.00 9,098.00 76,241.00 5,811.00
2015-12-31 164,639.00 10,591.00 75,746.00 5,585.00
2015-09-30 161,852.00 9,926.00 74,709.00 5,585.00
2015-06-30 157,167.00 9,311.00 72,317.00 5,585.00
2015-03-31 151,774.00 8,631.00 70,551.00 5,585.00
2014-12-31 148,167.00 6,608.00 69,423.00 4,547.00
2014-09-30 146,495.00 8,002.00 66,855.00 4,547.00
2014-06-30 143,900.00 7,676.00 65,396.00 4,547.00
2014-03-31 143,822.00 8,947.00 63,717.00 4,547.00
2013-12-31 139,613.00 9,183.00 61,343.00 4,062.00
2013-09-30 134,979.00 9,162.00 58,888.00 4,062.00
2013-06-30 130,707.00 8,260.00 57,762.00 4,062.00
2013-03-31 129,146.00 8,087.00 56,506.00 4,062.00
2012-12-31 125,397.00 8,259.00 55,785.00 3,717.00
2012-09-30 123,359.00 7,555.00 54,738.00 3,717.00
2012-06-30 122,787.00 7,943.00 53,739.00 3,717.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Rohto Pharmaceutical has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Rohto Pharmaceutical used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
  • Rohto Pharmaceutical has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Rohto Pharmaceutical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Rohto Pharmaceutical has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RPHC.F Health

 How is Rohto Pharmaceutical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Rohto Pharmaceutical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Rohto Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Rohto Pharmaceutical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Rohto Pharmaceutical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 19.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Rohto Pharmaceutical Company Filings, last reported 3 months ago.

OTCPK:RPHC.F Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 134,205.00 5,861.00 34,246.00
2018-09-30 134,089.00 6,373.00 30,799.00
2018-06-30 131,248.00 6,280.00 32,716.00
2018-03-31 128,439.00 5,853.00 30,532.00
2017-12-31 131,117.00 6,066.00 27,712.00
2017-09-30 123,305.00 6,063.00 24,311.00
2017-06-30 119,626.00 5,747.00 23,665.00
2017-03-31 118,435.00 5,118.00 23,924.00
2016-12-31 116,280.00 5,311.00 24,907.00
2016-09-30 109,508.00 4,907.00 18,504.00
2016-06-30 110,098.00 5,323.00 23,435.00
2016-03-31 111,269.00 5,446.00 23,073.00
2015-12-31 115,320.00 6,176.00 23,635.00
2015-09-30 113,561.00 7,422.00 26,685.00
2015-06-30 112,126.00 7,382.00 31,729.00
2015-03-31 110,513.00 9,423.00 25,733.00
2014-12-31 106,642.00 10,594.00 21,964.00
2014-09-30 100,738.00 10,569.00 19,773.00
2014-06-30 97,588.00 8,690.00 23,078.00
2014-03-31 98,625.00 9,882.00 23,028.00
2013-12-31 98,488.00 11,995.00 20,512.00
2013-09-30 100,205.00 7,530.00 24,521.00
2013-06-30 97,382.00 7,330.00 20,753.00
2013-03-31 93,769.00 7,189.00 19,868.00
2012-12-31 89,078.00 7,083.00 13,323.00
2012-09-30 85,086.00 6,759.00 14,057.00
2012-06-30 83,746.00 8,012.00 15,793.00
  • Rohto Pharmaceutical's level of debt (4.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (12.2% vs 4.4% today).
  • Debt is well covered by operating cash flow (367.3%, greater than 20% of total debt).
  • Rohto Pharmaceutical earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Rohto Pharmaceutical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Rohto Pharmaceutical has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RPHC.F Dividends

 What is Rohto Pharmaceutical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.77%
Current annual income from Rohto Pharmaceutical dividends. Estimated to be 0.82% next year.
If you bought $2,000 of Rohto Pharmaceutical shares you are expected to receive $15 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Rohto Pharmaceutical's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.4%).
  • Rohto Pharmaceutical's dividend is below the markets top 25% of dividend payers in United States of America (3.64%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:RPHC.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:RPHC.F Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2024-03-31
2023-03-31 27.00 1.00
2022-03-31 26.00 1.00
2021-03-31 25.67 3.00
2020-03-31 24.67 3.00
2019-03-31 23.67 3.00
OTCPK:RPHC.F Past Annualized Dividends Data
Date (Data in ¥) Dividend per share (annual) Avg. Yield (%)
2019-02-14 24.000 0.817
2019-02-13 24.000 0.800
2018-11-14 24.000 0.765
2018-11-13 24.000 0.694
2018-06-25 23.000 0.653
2018-05-11 23.000 0.652
2018-02-13 22.000 0.733
2018-02-09 22.000 0.791
2017-11-13 22.000 0.738
2017-11-10 22.000 0.789
2017-08-08 22.000 0.861
2017-06-26 22.000 0.956
2017-05-18 22.000 0.932
2017-02-13 22.000 1.032
2017-02-08 22.000 1.053
2016-11-14 22.000 1.232
2016-11-11 22.000 1.263
2016-08-08 21.000 1.226
2016-06-22 21.000 1.292
2016-05-13 21.000 1.247
2016-02-10 20.000 0.999
2016-02-09 20.000 1.001
2015-11-12 20.000 0.874
2015-11-11 20.000 0.916
2015-06-24 20.000 0.997
2015-05-14 20.000 1.102
2015-02-12 20.000 1.203
2015-02-06 20.000 1.319
2014-11-13 20.000 1.311
2014-11-11 20.000 1.279
2014-06-25 18.000 1.198
2014-05-14 18.000 1.144
2014-02-13 18.000 1.036
2014-02-07 18.000 1.106
2013-11-13 18.000 1.108
2013-11-12 18.000 1.200
2013-06-24 18.000 1.284
2013-05-15 18.000 1.242
2013-02-13 18.000 1.386
2013-02-07 18.000 1.512
2012-11-12 18.000 1.682
2012-11-09 18.000 1.705
2012-06-27 16.000 1.451
2012-05-11 16.000 1.757
2012-02-13 16.000 1.614
2012-02-09 16.000 1.710
2011-11-11 16.000 1.666
2011-11-10 16.000 1.690
2011-08-09 16.000 1.691
2011-05-11 16.000 1.813
2011-02-09 14.000 1.592
2010-11-10 14.000 1.485
2010-08-06 14.000 1.347
2010-08-05 14.000 1.333
2010-06-25 14.000 1.311
2010-05-11 14.000 1.327
2010-02-09 14.000 1.348
2009-11-12 13.000 1.191
2009-11-10 13.000 1.174
2009-06-26 13.000 1.151
2009-05-12 13.000 1.317
2009-04-27 14.000 1.577

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rohto Pharmaceutical is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
  • Rohto Pharmaceutical is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Rohto Pharmaceutical's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Rohto Pharmaceutical's dividends as it is not paying a notable one for United States of America.
Future Payout to shareholders
  • No need to calculate the sustainability of Rohto Pharmaceutical's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Rohto Pharmaceutical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Rohto Pharmaceutical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Rohto Pharmaceutical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RPHC.F Management

 What is the CEO of Rohto Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yamada Kunio
COMPENSATION ¥169,000,000
AGE 62
TENURE AS CEO 9.8 years
CEO Bio

Mr. Yamada Kunio has been the President at Rohto Pharmaceutical Co. Ltd. since June 9, 2009. Mr. Kunio has been the Chairman of the Board of Directors and Representative Director at Rohto Pharmaceutical Co. Ltd. since June 9, 2009. He led Rohto's visionary long term investments in R&D and directs the continuous and dramatic growth of sales. He is a young, energetic and dynamic leader with a progressive global vision for the growth and development of Rohto's shareholder value. He served as a Director of Signum Biosciences, Inc. He is a graduate of Japan's prestigious Tokyo University and has done post graduate work overseas.

CEO Compensation
  • Yamada's compensation has been consistent with company performance over the past year.
  • Yamada's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Rohto Pharmaceutical management team in years:

4.8
Average Tenure
66
Average Age
  • The tenure for the Rohto Pharmaceutical management team is about average.
Management Team

Yamada Kunio

TITLE
Chairman of the Board of Directors & President
COMPENSATION
¥169M
AGE
62
TENURE
9.8 yrs

Yoshino Toshiaki

TITLE
President
AGE
68
TENURE
9.8 yrs

Raju Juneja

TITLE
Executive VP of Overseas Business & Technology
AGE
66

Hideto Kamimura

TITLE
Senior Executive Officer and General Manager of Marketing Division

Kambara Yoichi

TITLE
MD & Head of Corporate Planning
AGE
70
TENURE
3.8 yrs

Raju Nishikawa

TITLE
Managing Director
TENURE
4.8 yrs

Kazuya Sugiura

TITLE
Senior Executive Officer and General Manager of Health & Beauty Business Division

Akiyoshi Yoshida

TITLE
VP & Director
AGE
76
TENURE
4.8 yrs

Kunisaki Shinichi

TITLE
Director of Management Strategy & Director
AGE
63
TENURE
1.8 yrs

Saito Masaya

TITLE
Director of Management Strategy Division & Director
AGE
55
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the Rohto Pharmaceutical board of directors in years:

9.3
Average Tenure
65.5
Average Age
  • The tenure for the Rohto Pharmaceutical board of directors is about average.
Board of Directors

Yamada Kunio

TITLE
Chairman of the Board of Directors & President
COMPENSATION
¥169M
AGE
62
TENURE
9.8 yrs

Yoshino Toshiaki

TITLE
President
AGE
68
TENURE
14.8 yrs

Raju Juneja

TITLE
Executive VP of Overseas Business & Technology
AGE
66
TENURE
4.8 yrs

Akiyoshi Yoshida

TITLE
VP & Director
AGE
76
TENURE
19.4 yrs

Kunisaki Shinichi

TITLE
Director of Management Strategy & Director
AGE
63
TENURE
8.8 yrs

Saito Masaya

TITLE
Director of Management Strategy Division & Director
AGE
55
TENURE
7.8 yrs

Yamada Yasuhiro

TITLE
Director
AGE
80
TENURE
45.4 yrs

Mari Matsunaga

TITLE
External Director
AGE
64
TENURE
4.8 yrs

Shingo Torii

TITLE
External Director
AGE
65
TENURE
3.8 yrs

Masaaki Uneme

TITLE
Standing Corporate Auditor
AGE
72
TENURE
9.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Rohto Pharmaceutical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Rohto Pharmaceutical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RPHC.F News

Simply Wall St News

RPHC.F Company Info

Description

Rohto Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. It offers eye care products, such as eye drops, care for contact lenses, and eye wash; facial care products comprising face wash, lotions, and creams under the Obagi and Hada-Labo brands; medicine and medicated products for skin; medicine for internal use, such as digestive and herbal medicines; oral medicines comprising gastrointestinal medicines and supplements; and non-prescription medicines. The company also operates beauty counters that provide beauty and health services. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co., Ltd. in 1949. Rohto Pharmaceutical Co., Ltd. was founded in 1899 and is headquartered in Osaka, Japan.

Details
Name: Rohto Pharmaceutical Co., Ltd.
RPHC.F
Exchange: OTCPK
Founded: 1899
¥3,161,696,620
113,968,726
Website: http://www.rohto.co.jp
Address: Rohto Pharmaceutical Co., Ltd.
1-8-1, Tatsumi-nishi,
Ikuno-ku,
Osaka,
544-8666,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4527 Common Stock The Tokyo Stock Exchange JP JPY 06. Jan 1992
OTCPK RPHC.F Common Stock Pink Sheets LLC US USD 06. Jan 1992
Number of employees
Current staff
Staff numbers
6,448
Rohto Pharmaceutical employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 00:12
End of day share price update: 2019/01/24 00:00
Last estimates confirmation: 2019/04/10
Last earnings filing: 2019/02/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.